Stress Facilitates the Development of Cognitive Dysfunction After Chronic Ethanol Exposure
Overview
Authors
Affiliations
Background: Chronic exposure to stress or alcohol can drive neuroadaptations that alter cognition. Alterations in cognition may contribute to alcohol use disorders by reducing cognitive control over drinking and maintenance of abstinence. Here we examined effects of combined ethanol (EtOH) and stress exposure on prefrontal cortex (PFC)-dependent cognition.
Methods: Adult male C57BL/6J mice were trained to drink EtOH (15%, v/v) on a 1 h/d 1-bottle schedule. Once stable, mice were exposed to cycles of chronic intermittent EtOH (CIE) or air-control vapor exposure (Air), followed by test cycles of 1 h/d EtOH drinking. During test drinking, mice received no stress (NS) or 10 minutes of forced swim stress (FSS) 4 hours before each test. This schedule produced 4 experimental groups: control, Air/NS; EtOH-dependent no stress, CIE/NS; nondependent stress, Air/FSS; or EtOH-dependent stress, CIE/FSS. After 2 cycles of CIE and FSS exposure, we assessed PFC-dependent cognition using object/context recognition and attentional set shifting. At the end of the study, mice were perfused and brains were collected for measurement of c-Fos activity in PFC and locus coeruleus (LC).
Results: CIE/FSS mice escalated EtOH intake faster than CIE/NS and consumed more EtOH than Air/NS across all test cycles. After 2 cycles of CIE/FSS, mice showed impairments in contextual learning and extradimensional set-shifting relative to other groups. In addition to cognitive dysfunction, CIE/FSS mice demonstrated widespread reductions in c-Fos activity within prelimbic and infralimbic PFC as well as LC.
Conclusions: Together, these findings show that interactions between EtOH and stress exposure rapidly lead to disruptions in signaling across cognitive networks and impairments in PFC-dependent cognitive function.
Investigating whether alcohol is transformed to norepinephrine or dopamine in the mouse brain.
Wlaz P, Fitzgerald P, Zmudzki P, Socala K Pharmacol Rep. 2025; .
PMID: 40069538 DOI: 10.1007/s43440-025-00708-7.
Nippert K, Rowland C, Vazey E, Moorman D Neuropharmacology. 2024; 260:110114.
PMID: 39134298 PMC: 11694314. DOI: 10.1016/j.neuropharm.2024.110114.
Rodberg E, Vazey E Alcohol. 2022; 101:37-43.
PMID: 35395359 PMC: 9118340. DOI: 10.1016/j.alcohol.2022.03.003.
Charlton A, Perry C Front Neurosci. 2022; 16:836827.
PMID: 35360176 PMC: 8960615. DOI: 10.3389/fnins.2022.836827.
Haun H, Lebonville C, Solomon M, Griffin W, Lopez M, Becker H Biol Psychiatry. 2022; 91(12):1019-1028.
PMID: 35190188 PMC: 9167153. DOI: 10.1016/j.biopsych.2022.01.002.